| Dr Arjun K Theertham, MD | |
|
1145 Bordentown Ave, Parlin, NJ 08859-1851 | |
| (732) 727-0400 | |
| Not Available |
| Full Name | Dr Arjun K Theertham |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 9 Years |
| Location | 1145 Bordentown Ave, Parlin, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679956981 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayshore Medical Center | Holmdel, NJ | Hospital |
| Jersey Shore University Medical Center | Neptune, NJ | Hospital |
| Riverview Medical Center | Red bank, NJ | Hospital |
| Raritan Bay Medical Center Perth Amboy Division | Perth amboy, NJ | Hospital |
| Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Younan Group Pa | 9436537909 | 9 |
News Archive
They will examine the social and behavioural aspects of dining and their potential impact on school attendance and attitudes to learning.
A screening program for chronic kidney disease (CKD) initiated in Canada has successfully identified a high proportion of individuals with risk factors for CKD as well as many with unrecognized CKD.
GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company's lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children's Hospital & Research Center Oakland in California.
The hearings represent the first of what will likely be a long list of hearings and new legislation designed to question and denounce the new health law. With the measure in the spotlight, the debate surrounding its fiscal impact also is a "hot topic." Meanwhile, some Democrats who last year opposed the health overhaul are starting to find value in it.
› Verified 3 days ago
| Entity Name | Rutgers Health-rwj Family Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780766527 PECOS PAC ID: 9032174271 Enrollment ID: O20041130000005 |
News Archive
They will examine the social and behavioural aspects of dining and their potential impact on school attendance and attitudes to learning.
A screening program for chronic kidney disease (CKD) initiated in Canada has successfully identified a high proportion of individuals with risk factors for CKD as well as many with unrecognized CKD.
GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company's lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children's Hospital & Research Center Oakland in California.
The hearings represent the first of what will likely be a long list of hearings and new legislation designed to question and denounce the new health law. With the measure in the spotlight, the debate surrounding its fiscal impact also is a "hot topic." Meanwhile, some Democrats who last year opposed the health overhaul are starting to find value in it.
› Verified 3 days ago
| Entity Name | Rutgers Health-rwj Pediatric Critical Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780766527 PECOS PAC ID: 1355390287 Enrollment ID: O20050119000070 |
News Archive
They will examine the social and behavioural aspects of dining and their potential impact on school attendance and attitudes to learning.
A screening program for chronic kidney disease (CKD) initiated in Canada has successfully identified a high proportion of individuals with risk factors for CKD as well as many with unrecognized CKD.
GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company's lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children's Hospital & Research Center Oakland in California.
The hearings represent the first of what will likely be a long list of hearings and new legislation designed to question and denounce the new health law. With the measure in the spotlight, the debate surrounding its fiscal impact also is a "hot topic." Meanwhile, some Democrats who last year opposed the health overhaul are starting to find value in it.
› Verified 3 days ago
| Entity Name | Rwjbh Emergency Medicine Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912510041 PECOS PAC ID: 0941612840 Enrollment ID: O20201217002547 |
News Archive
They will examine the social and behavioural aspects of dining and their potential impact on school attendance and attitudes to learning.
A screening program for chronic kidney disease (CKD) initiated in Canada has successfully identified a high proportion of individuals with risk factors for CKD as well as many with unrecognized CKD.
GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company's lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children's Hospital & Research Center Oakland in California.
The hearings represent the first of what will likely be a long list of hearings and new legislation designed to question and denounce the new health law. With the measure in the spotlight, the debate surrounding its fiscal impact also is a "hot topic." Meanwhile, some Democrats who last year opposed the health overhaul are starting to find value in it.
› Verified 3 days ago
| Entity Name | The Younan Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023757978 PECOS PAC ID: 9436537909 Enrollment ID: O20220908001001 |
News Archive
They will examine the social and behavioural aspects of dining and their potential impact on school attendance and attitudes to learning.
A screening program for chronic kidney disease (CKD) initiated in Canada has successfully identified a high proportion of individuals with risk factors for CKD as well as many with unrecognized CKD.
GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company's lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children's Hospital & Research Center Oakland in California.
The hearings represent the first of what will likely be a long list of hearings and new legislation designed to question and denounce the new health law. With the measure in the spotlight, the debate surrounding its fiscal impact also is a "hot topic." Meanwhile, some Democrats who last year opposed the health overhaul are starting to find value in it.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Arjun K Theertham, MD 601 N 30th St - Cu Department Of Internal Medicine, Omaha, NE 68131 Ph: (402) 717-0800 | Dr Arjun K Theertham, MD 1145 Bordentown Ave, Parlin, NJ 08859-1851 Ph: (732) 727-0400 |
News Archive
They will examine the social and behavioural aspects of dining and their potential impact on school attendance and attitudes to learning.
A screening program for chronic kidney disease (CKD) initiated in Canada has successfully identified a high proportion of individuals with risk factors for CKD as well as many with unrecognized CKD.
GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company's lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children's Hospital & Research Center Oakland in California.
The hearings represent the first of what will likely be a long list of hearings and new legislation designed to question and denounce the new health law. With the measure in the spotlight, the debate surrounding its fiscal impact also is a "hot topic." Meanwhile, some Democrats who last year opposed the health overhaul are starting to find value in it.
› Verified 3 days ago
Dr. Abrar Khan, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 499 Ernston Rd, Parlin, NJ 08859 Phone: 732-707-4676 Fax: 732-372-0211 | |
Dr. Zyad Younan, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1145 Bordentown Ave, Suite 10, Parlin, NJ 08859 Phone: 732-727-0400 Fax: 732-727-1391 | |
Gugu Mohapeloa, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1145 Bordentown Ave, #18, Parlin, NJ 08859 Phone: 732-727-4700 Fax: 732-727-4734 | |
Michael Piscopiello, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1145 Bordentown Ave, Suite 10, Parlin, NJ 08859 Phone: 732-727-5371 Fax: 737-727-5371 | |
K. George Younan, MD PA Internal Medicine Medicare: Medicare Enrolled Practice Location: 1145 Bordentown Ave, Ste #10, Parlin, NJ 08859 Phone: 732-727-0400 Fax: 732-727-1391 | |
Dr. Mekhala Ashok Mathure, M.B.B.S,M.A, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1145 Bordentown Ave Ste 4, Parlin, NJ 08859 Phone: 732-553-1901 Fax: 732-553-1903 |